DetermaIO Assay Helps Inform Benefit With Single-Agent Immunotherapy in Advanced NSCLC

November 22, 2022Caroline SeymourThe score of the 27-gene Determa immune-oncology assay demonstrated a correlation with overall survival and progression-free survival in patients with advanced non–sma

Updated on: October 17,2023

DetermaIO Assay Helps Inform Benefit With Single-Agent Immunotherapy in Advanced NSCLC

November 22, 2022Caroline SeymourThe score of the 27-gene Determa immune-oncology assay demonstrated a correlation with overall survival and progression-free survival in patients with advanced non–sma

Updated on:October 17,2023

Adding immunotherapy to chemotherapy regimen improves survival in metastatic bladder cancer patients

byThe Mount Sinai HospitalCredit: Unsplash/CC0 Public DomainA clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy with immunotherapy resulted in improve

Updated on: October 23,2023

Adding immunotherapy to chemotherapy regimen improves survival in metastatic bladder cancer patients

byThe Mount Sinai HospitalCredit: Unsplash/CC0 Public DomainA clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy with immunotherapy resulted in improve

Updated on:October 23,2023

Addition of maintenance olaparib slows advanced ovarian cancer

(HealthDay)—Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovaria

Updated on: December 22,2023

Addition of maintenance olaparib slows advanced ovarian cancer

(HealthDay)—Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovaria

Updated on:December 22,2023

Proton therapy lowers risk of side effects in cancer compared to traditional radiation

byPerelman School of Medicine at the University of PennsylvaniaStudy finds protons led to two-thirds reduction in unplanned hospitalizations. Credit: Penn MedicineProton therapy leads to signifi

Updated on: December 20,2023

Proton therapy lowers risk of side effects in cancer compared to traditional radiation

byPerelman School of Medicine at the University of PennsylvaniaStudy finds protons led to two-thirds reduction in unplanned hospitalizations. Credit: Penn MedicineProton therapy leads to signifi

Updated on:December 20,2023

Discovery of a protein controlling resistance to chemotherapy

byUniversité libre de BruxellesEMT is associated with intrinsic resistance to chemotherapy in SCCs. Credit:Nature(2023). DOI: 10.1038/s41586-023-05838-7Despite the recent development

Updated on: December 21,2023

Discovery of a protein controlling resistance to chemotherapy

byUniversité libre de BruxellesEMT is associated with intrinsic resistance to chemotherapy in SCCs. Credit:Nature(2023). DOI: 10.1038/s41586-023-05838-7Despite the recent development

Updated on:December 21,2023

A new mechanism of drug resistance discovered for breast cancer

by Universita Cattolica del Sacro CuoreEmergence of CSCs following IFN-I treatment.a, Multiparametric flow cytometry analysis of the illustrated CSC surface markers in MCA205 and AT3 cells treat

Updated on: December 21,2023

A new mechanism of drug resistance discovered for breast cancer

by Universita Cattolica del Sacro CuoreEmergence of CSCs following IFN-I treatment.a, Multiparametric flow cytometry analysis of the illustrated CSC surface markers in MCA205 and AT3 cells treat

Updated on:December 21,2023

P53 could be key to therapies for salivary gland cancer

Mouse models show that activating a non-mutated form of the gene could lead to developing therapies for salivary gland cancer.Researchers at the University of Michigan Rogel Cancer Center and School o

Updated on: October 31,2023

P53 could be key to therapies for salivary gland cancer

Mouse models show that activating a non-mutated form of the gene could lead to developing therapies for salivary gland cancer.Researchers at the University of Michigan Rogel Cancer Center and School o

Updated on:October 31,2023

UC San Diego Moores administers its first personalized cancer vaccine

by Paul Sisson, The San Diego Union-TribuneCredit: Min Yu (Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC),USC Norris Comprehensive Cancer CenterMore than 18 round

Updated on: December 18,2023

UC San Diego Moores administers its first personalized cancer vaccine

by Paul Sisson, The San Diego Union-TribuneCredit: Min Yu (Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC),USC Norris Comprehensive Cancer CenterMore than 18 round

Updated on:December 18,2023

FAM3C encapsulated in circulating tumor-derived extracellular vesicles promotes distant growth in lung cancers

byNational University of SingaporeTumor-derived EVs containing FAM3C trigger aggressiveness of lung carcinoma cells in vivo. (A) Tail vein injection of A549 lung carcinoma cells in mouse model a

Updated on: December 19,2023

FAM3C encapsulated in circulating tumor-derived extracellular vesicles promotes distant growth in lung cancers

byNational University of SingaporeTumor-derived EVs containing FAM3C trigger aggressiveness of lung carcinoma cells in vivo. (A) Tail vein injection of A549 lung carcinoma cells in mouse model a

Updated on:December 19,2023

Uprooting cancer: Hydrogel rapidly reverts cancer cells back to cancer stem cells

A hydrogel developed at Hokkaido University successfully reverted cancer cells back to cancer stem cells within 24 hours in six different human cancer types. This could lead to the development of anti

Updated on: November 02,2023

Uprooting cancer: Hydrogel rapidly reverts cancer cells back to cancer stem cells

A hydrogel developed at Hokkaido University successfully reverted cancer cells back to cancer stem cells within 24 hours in six different human cancer types. This could lead to the development of anti

Updated on:November 02,2023

Low long-term risk of breast cancer recurrence after nipple-sparing mastectomy

byWolters Kluwer HealthCredit: Pixabay/CC0 Public DomainNipple-sparing mastectomy (NSM)—an increasingly popular option for women undergoing treatment for breast cancer—not only achieves good cos

Updated on: December 19,2023

Low long-term risk of breast cancer recurrence after nipple-sparing mastectomy

byWolters Kluwer HealthCredit: Pixabay/CC0 Public DomainNipple-sparing mastectomy (NSM)—an increasingly popular option for women undergoing treatment for breast cancer—not only achieves good cos

Updated on:December 19,2023

Cilta-cel Provides Durable Responses in Lenalidomide-Refractory Myeloma After 1 to 3 Prior Lines

August 28, 2022Kristi RosaCiltacabtagene autoleucel elicited encouraging responses in patients with multiple myeloma who had received 1 to 3 prior lines of therapy and were refractory to lenalidomide.

Updated on: October 17,2023

Cilta-cel Provides Durable Responses in Lenalidomide-Refractory Myeloma After 1 to 3 Prior Lines

August 28, 2022Kristi RosaCiltacabtagene autoleucel elicited encouraging responses in patients with multiple myeloma who had received 1 to 3 prior lines of therapy and were refractory to lenalidomide.

Updated on:October 17,2023